阿托伐他汀没有增加绝经后妇女的骨密度
Atorvastatin No Help to Bone in Postmenopausal Women阿托伐他汀对绝经后妇女的骨质疏松没有帮助
By David Douglas
NEW YORK (Reuters Health) Jan 08 - Atorvastatin, at doses that lower lipid levels, appears to have no effect on bone mineral density or bone metabolism in postmenopausal women, according to researchers.
纽约（路透社健康新闻）1月8日－研究者们声称：阿托伐他汀，在它能降低血脂水平的剂量，对于绝经后妇女的骨密度或骨代谢没有影响。
\"Laboratory evidence and observational clinical trials suggested that statins may have very favorable effects on the skeleton,\" senior investigator Dr. Michael R. McClung told Reuters Health. \"This study demonstrates clearly that statins do not have effects on bone in the clinical setting.\"
“实验室证据以及临床研究的观测都提示，他汀类药物可能对骨的作用有良好的作用。” Michael R. McClung博士，也是这次研究的首席研究者对路透社记者透露，“而这项研究明确告诉大家：他汀类药物在临床剂量对于骨的作用没有影响。”
In the December issue of the Journal of Clinical Endocrinology and Metabolism, Dr. McClung, of the Oregon Osteoporosis Center, Portland, and colleagues note that there is some evidence that statins may increase bone formation and reduce bone resorption. However, trials aimed primarily at lipid lowering effects have yielded inconsistent results in this regard.
在12月刊的《临床内分泌与代谢杂志》上，McClung医生和他的同事们发表文章声称：尽管一些证据显示他汀类药物能增加骨声称及减少骨吸收，但是在一个以降低血脂作为首要目的的临床研究中却得到了上述不同的结果。McClung医生目前就职于位于Portland的俄亥俄骨质疏松中心。
To investigate further, the researchers studied 626 postmenopausal women with LDL cholesterol levels of at least 130 mg/dL. They were randomized to treatment with 10, 20, 40 or 80 mg of atorvastatin daily or to placebo.
为了进一步的研究，研究者们研究了626位绝经后妇女，这些妇女的低密度脂蛋白的水平至少是130 mg/dL。她们随机的用10mg，20mg，40mg，或是80mg的阿托伐他汀或安慰剂治疗。
At 52 weeks, all of the active treatment groups showed significant reduction in LDL cholesterol from baseline and compared to placebo. The treatment was also well tolerated.
在治疗的第52周，所有使用阿托伐他汀治疗的患者，其低密度脂蛋白水平不管是基线水平还是与安慰剂比较都显著降低。
However, the researchers \"found no evidence that systemic atorvastatin administration produced any significant effect on bone mass or markers.\"
但是研究者们发现：系统使用阿托伐他汀对骨量或骨的标记物没有显著影响。
Dr. Henry G. Bone of the Michigan Bone and Mineral Clinic, Detroit, told Reuters Health that \"our study pretty well eliminates the likelihood that conventional therapy with such agents would have a clinically significant beneficial or harmful effect on bone metabolism.\"
Henry G医生是位于Detroit的美国密歇根州的骨与矿物质临床研究所的骨代谢方面的专家，她对路透社的记者透露，“我们的研究对于明确这类药物的常规治疗对于骨代谢是否有显著的有利影响或是不良影响而言是十分有意义的。”
页:
[1]